Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | PROKR1 | Q8TCW9 | 4/20 | 0.39 |
| ▸ | PGR | P06401 | 2/20 | 0.39 |
| ▸ | AR | P10275 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 9/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23091733 | 0.87 | EPHX2 (0.51) | PROKR1AREPHX2MEN1KMT2A | |
| SCHEMBL29693489 | 0.87 | EPHX2 (0.51) | PROKR1AREPHX2MEN1KMT2A | |
| SCHEMBL21722797 | 0.84 | AR (0.35) | RBP4AR | |
| SCHEMBL21722975 | 0.74 | MEN1 (0.43) | RBP4CYP3A4CYP2C9CYP2C19MEN1 | |
| SCHEMBL22462783 | 0.73 | AR (0.40) | CYP3A4CYP2C19AREPHX2MEN1 | |
| SCHEMBL30272618 | 0.73 | AR (0.40) | CYP3A4CYP2C19AREPHX2MEN1 | |
| SCHEMBL21722949 | 0.72 | EPHX2 (0.48) | EPHX2MEN1KMT2A | |
| SCHEMBL22462777 | 0.70 | KDM1A (0.37) | MEN1KMT2A | |
| SCHEMBL1983309 | 0.69 | AKR1C3 (0.53) | CYP3A4EPHX2 | |
| SCHEMBL2201245 | 0.67 | SMN1; SMN2 (0.50) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3837263-B1 | NEW HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2024-07-03 | — | — | EP | disclosed |
| US-20240150373-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2024-05-09 | — | — | US | disclosed |
| US-11802133-B2 | Heterocyclic compounds as monoacylglycerol lipase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230050901-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2023-02-16 | — | — | US | disclosed |
| EP-4028402-A1 | RADIOLABELED COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2022-07-20 | — | — | EP | disclosed |
| US-20220202963-A1 | RADIOLABELED COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2022-06-30 | — | — | US | disclosed |
| US-20210277020-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2021-09-09 | — | — | US | disclosed |
| EP-3837264-A1 | NEW HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2021-06-23 | — | — | EP | disclosed |
| EP-3837263-A1 | NEW HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2021-06-23 | — | — | EP | disclosed |
| WO-2021048241-A1 | RADIOLABELED COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-03-18 | — | — | WO | disclosed |
| WO-2020035424-A1 | NEW HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2020-02-20 | — | — | WO | disclosed |
| WO-2020035425-A1 | NEW HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210277020-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | MGLL, PNLIP, LPL | RBP4 4113/4885CYP3A4 1459/4885CYP2C9 719/4885 |
| US-20240150373-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | LIPC, LPL, MGLL | RBP4 3713/4885CYP3A4 497/4885CYP2C9 336/4885 |
| US-11802133-B2 | Heterocyclic compounds as monoacylglycerol lipase inhibitors | LIPC, LPL, MGLL | RBP4 3713/4885CYP3A4 497/4885CYP2C9 336/4885 |
| US-20220202963-A1 | RADIOLABELED COMPOUNDS | MGLL, PNLIP, LPL | RBP4 3318/4885CYP3A4 2599/4885CYP2C9 2650/4885 |
| US-20230050901-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | LIPC, LPL, MGLL | RBP4 3713/4885CYP3A4 497/4885CYP2C9 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.